Journal of International Oncology››2024,Vol. 51››Issue (5): 312-315.doi:10.3760/cma.j.cn371439-20240119-00053
Previous ArticlesNext Articles
Received:2024-01-19Revised:2024-04-01Online:2024-05-08Published:2024-06-26
"
"
"
"
"
"
| [1] | Wang W, Li G. Incidence and prognostic factors of hepatoid adenocarcinoma: a population-based analysis[J].Transl Cancer Res,2020,9(9): 5401-5410. DOI:10.21037/tcr-20-1126. pmid:35117905 |
| [2] | Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J].Gastric Cancer, 2021,24(1): 1-21. DOI:10.1007/s10120-020-01042-y. |
| [3] | Chen X, Li AQ, Wang QX, et al. Hepatoid adenocarcinoma in the peritoneal cavity: two case reports[J].Medicine (Baltimore),2019,98(5): e14226. DOI:10.1097/MD.0000000000014226. |
| [4] | Zhou K, Wang QN, Ao S, et al. The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis[J].BMC Cancer,2020,20(1): 671. DOI:10.1186/s12885-020-07031-9. pmid:32680468 |
| [5] | Zhang ZR, Wu J, Li HW, et al. Hepatoid adenocarcinoma of the stomach: thirteen case reports and review of literature[J].World J Clin Cases,2020,8(6): 1164-1171. DOI:10.12998/wjcc.v8.i6. 1164. |
| [6] | He F, Fu Y, Sun Q, et al. Integrated clinicopathological and immunohistochemical analysis of gastric adenocarcinoma with hepatoid differentiation: an exploration of histogenesis, molecular characteristics, and prognostic markers[J].Hum Pathol,2021,115: 37-46. DOI:10.1016/j.humpath.2021.02.003. |
| [7] | Søreide JA. Therapeutic approaches to gastric hepatoid adenocarcinoma: current perspectives[J].Ther Clin Risk Manag,2019,15: 1469-1477. DOI:10.2147/TCRM.S204303. |
| [8] | Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J].Lancet Oncol,2014,15(11): 1224-1235. DOI:10.1016/S1470-2045(14)70420-6. pmid:25240821 |
| [9] | Søreide JA. Therapeutic approaches to gastric hepatoid adenocarcinoma: current perspectives[J].Ther Clin Risk Manag,2019,15: 1469-1477. DOI:10.2147/TCRM.S204303. |
| [10] | Baek SK, Han SW, Oh DY, et al. Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer[J].BMC Gastroenterol,2011,11: 56. DOI:10.1186/1471-230X-11-56. pmid:21592404 |
| [11] | Yoshizawa J, Ishizone S, Ikeyama M, et al. Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature[J].BMC Cancer,2017,17(1): 368. DOI:10.1186/s12885-017-3357-7. pmid:28545511 |
| [12] | Doi Y, Takii Y, Mitsugi K, et al. The Effectiveness of hepatic arterial infusion chemotherapy with 5-fluorouracil/cisplatin and systemic chemotherapy with ramucirumab in alpha-fetoprotein-producing gastric cancer with multiple liver metastases[J].Case Rep Oncol Med,2018,2018: 5402313. DOI:10.1155/2018/5402313. |
| [13] | Li W, Li Q, Yu YY, et al. Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma[J].Cancer Manag Res,2020,12: 11113-11119. DOI:10.2147/CMAR.S276969. pmid:33173344 |
| [14] | Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J].Lancet,2010,376(9742):687-697. DOI:10.1016/S0140-6736(10)61121-X. |
| [15] | Arakawa Y, Tamura M, Aiba K, et al. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report[J].Oncol Lett,2017,14(3): 3039-3042. DOI:10.3892/ol.2017.6514. pmid:28928842 |
| [16] | Lin JX, Wang ZK, Hong QQ, et al. Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach[J].JAMA Netw Open,2021,4(10): e2128217. DOI:10.1001/jamanetworkopen.2021.28217. |
| [17] | Kamei SG, Kono K, Amemiya H, et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein[J].J Gastroenterol,2003,38(6): 540-547. DOI:10.1007/s00535-002-1099-y. pmid:12825129 |
| [18] | Mei Y, Li M, Wen J, et al. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer[J].Cancer Med,2023,12(10): 12018-12033. DOI:10.1002/cam4.5883. |
| [19] | Fang YU, Wang L, Yang N, et al. Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases[J].Oncol Lett,2015,10(5): 3021-3025. DOI:10.3892/ol.2015.3731. pmid:26722283 |
| [20] | Xia R, Zhou Y, Wang Y, et al. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments[J].Front Oncol,2021,11: 633916. DOI:10.3389/fonc.2021.633916. |
| [21] | Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice[J].Science,1997,276(5317): 1423-1425. DOI:10.1126/science.276.5317.1423. pmid:9162011 |
| [22] | Xu JM, Shen L, Zhou ZW, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study[J].Lancet Oncol,2020,21(11): 1500-1512. DOI:10.1016/S1470-2045(20)30496-4. pmid:32966811 |
| [23] | Cao YS, Lu M, Sun Y, et al. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial[J].J Cancer Res Clin Oncol,2023,149(2): 779-789. DOI:10.1007/s00432-021-03898-8. |
| [24] | Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J].Cell,2017,168(4): 707-723. DOI:10.1016/j.cell.2017.01.017. pmid:28187290 |
| [25] | Ho WJ, Jaffee EM. Macrophage-targeting by CSF1/1R blockade in pancreatic cancers[J].Cancer Res,2021,81(24): 6071-6073. DOI:10.1158/0008-5472.CAN-21-3603. pmid:34911778 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
